Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with severe organ dysfunction.
Allogeneic stem cell transplantation (SCT) can cure several nonmalignant diseases in children. However, patients frequently have significant morbidity before transplantation and there is a high transplant-related mortality. Nonmyeloablative SCT might achieve the same goals but with less toxicity. Six pediatric patients with nonmalignant diseases underwent nonmyeloablative SCT from different stem cell sources. All patients were conditioned with fludarabine/melphalan with additional anti-thymocyte globulin for haploidentical grafts and prophylaxis for graft-versus-host disease (GVHD) consisting of tacrolimus and methotrexate with additional prednisolone for haploidentical grafts. Hematopoietic stem cells were neither T-cell depleted nor purged. All patients had severe organ dysfunction that precluded transplantation with conventional conditioning. Five of the six are alive and in complete disease resolution at a median of 19 months (range, 7-53 months) after SCT. One patient died of bacteremia before engraftment. Three patients achieved complete donor chimerism. Two patients remained stable mixed chimerism. Short-term toxicities were minimal. Acute and chronic GVHD were not seen. In summary, the fludarabine-based nonmyeloablative regimen followed by SCT provides a good approach for children with nonmalignant diseases. Even patients with severe organ dysfunctions had adequate engraftment with acceptable toxicities.
Kikuta
A
A
Department of Pediatrics, Fukushima Medical University School of Medicine, I Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan. akikuta@fmu.ac.jp
Ito
M
M
Mochizuki
K
K
Akaihata
M
M
Nemoto
K
K
Sano
H
H
Ohto
H
H
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D020031:Epstein-Barr Virus Infections / Q000628:therapy; D005260:Female; D006105:Granulomatous Disease, Chronic / Q000628:therapy; D006801:Humans; D053306:Hyper-IgM Immunodeficiency Syndrome / Q000628:therapy; D007223:Infant; D008297:Male; D016511:Severe Combined Immunodeficiency / Q000628:therapy; D033581:Stem Cell Transplantation; D018183:Transplantation Chimera; D019172:Transplantation Conditioning